China’s rapid growth in clinical trials and biotechnology has been a focal point of the global industry. Understanding this ecosystem’s latest trends and evolution is essential for companies looking to expand their operations or collaborate with partners in China. Similarly, Australia’s regulatory environment plays a crucial role in the success of clinical trials conducted in the country.
The collaboration between China and Australia holds immense potential for clinical trial and biotech industries. This webinar explores the current landscape of clinical trials and the biotech ecosystem in China and sheds light on trends and evolutionary patterns. Participants will gain insights into strategies for more effective partnerships between Chinese and Australian companies.
Read more...
This webinar will also provide attendees with a good overview of the regulatory pathway in Australia, including key considerations for data governance, technology adoption and stakeholder engagement.
Overall, this webinar offers industry professionals a valuable opportunity to gain insights into the clinical trial landscapes in China and Australia and discover practical strategies for maximizing collaboration and ensuring successful outcomes. This includes identifying common areas of interest, leveraging each other’s strengths and navigating potential challenges. The discussion will also cover the importance of cultural understanding and effective communication in cross-border collaborations.
Read Less...
Register for this webinar today to gain insights into conducting clinical trials in Australia and discover practical strategies for maximizing collaboration between China and Australia.
Speakers
(Moderator) Tam Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne
Associate Professor Tam Nguyen has close to 25 years of experience of working in clinical trials, health and medical research and the research management sector, including tertiary teaching hospitals, medical research institutes and universities across Australia.
Tam is the Deputy Director of Research at St. Vincent’s Hospital Melbourne and is responsible for research strategy, research development and innovation. Tam serves as a Non-Executive Director and Advisor to several MedTech and HealthTech start-ups and scale-ups.
Read more...
Read Less...
Dr. Robert Lin, CEO, GreenLight Clinical
Dr. Robert Lin is the CEO of Greenlight Clinical. He is a highly qualified healthcare executive with over 20 years of clinical and managerial experience.
As a healthcare professional who is passionate about advancing medical facilities, treatments and patient-centric care, Dr. Lin has extensive experience in managing private, public and international hospitals and other facilities. His expertise in this area spans strategic planning, improving operational efficiency, team building and project management.
Read more...
Dr. Lin’s professional insights are widely published, and he is a reviewer and invited author of the Journal of Medical Radiation Sciences.
As someone who drives positive development in the healthcare industry, Dr. Lin believes that optimal outcomes and improved patient experiences are best achieved through understanding difficult concepts, turning ideas into logical strategies and implementing appropriate systems.
Read Less...
Nate Zhang, VP, GM Overseas Business, Taimei Technology
Nate Zhang is a global leader and pioneer of digital health and digital transformation, currently leading Taimei Technology’s international business expansion. He has more than 15 years of experience in enterprise software and healthcare industries across three continents (Asia, North America and Europe) covering both developed and developing markets.
Prior to Taimei, Nate was the Founder of Alibaba Cloud’s digital health ecosystem and was leading the digital health solutions and Global-ISV solutions of Alibaba Cloud.
Read more...
He is also the Founder of Medtronic’s digital health team and Founder of Medtronic XR Lab. During this period, Nate and his team invented the remote self-service follow-up machine for pacemaker patients in China, followed by successful commercialization through the Shanghai International Import Expo. Nate and his team also developed China’s first AR-based surgical training and guidance system of percutaneous coronary intervention for bifurcation lesions “AR Bifur,” which benefits thousands of physicians in China. Nate was also one of the early core members of Veeva Systems in China.
Read Less...
Lisa Nelson, CEO, Scientia Clinical Research
Lisa Nelson has 30 years of clinical trial experience with extensive Phase I experience, both local and international, including the design, establishment and running of Scientia Clinical Research, Nucleus Network and Linear Clinical Research. A leader in her field, Lisa is the CEO of Scientia Clinical Research: the first purpose-built, early-phase clinical trial facility in NSW. Integral to this success is Lisa’s knowledge and experience in setting up and managing globally recognised Phase I units in other states, creating new business opportunities, developing key client relationships and keeping abreast of developments in early-phase drug and device research. The US and China are her prime focus. Lisa has very broad and insightful perspective on what is happening in the pharmaceutical and biotechnology world today.
Message Presenter
Dr. Hui Zhou, SVP, Clinical Development for New Drugs, Innovent Biologics
Dr. Hui Zhou, MD, is SVP of Clinical Development for New Drugs. In January 2016, Dr. Hui joined Innovent and was responsible for and leading the clinical development, registration and marketing of several tumor products, including Sintilimad. Currently, Dr. Hui is responsible for clinical development, research design and executive management of new drugs in the oncology field.
He has worked in clinical development or medical affairs in the medical or R&D departments of Astrazeneca, Amgen and Roche. Before joining the pharmaceutical industry, he worked at Zhongshan Hospital, which is affiliated to Fudan University. He is also a member of the following committees: Clinical Research Committee of China Anti-Cancer Association; the Clinical Research Committee of Chinese Society of Clinical Oncology; Translational Medicine Committee, Chinese Society of Clinical Oncology; and Clinical Trial Committee, China Pharmaceutical Innovation Promotion Association.
Message PresenterWho Should Attend?
This webinar will appeal to C-Suite executives and professionals in biotech, pharma and CROs working within:
- Clinical innovation and strategy
- Clinical development and market access
- Business development and partnerships
- Cross-border — China and Australia
What You Will Learn
Attendees will learn about:
- How does the clinical trials and biotech ecosystem look like in China today
- How can Chinese and Australian companies partner more effectively
- Regulatory pathway in Australia: data governance, technology and stakeholders
- How dynamics between sites, investigators and recruitment change depending on the therapy area
Xtalks Partner
Taimei Technology
Taimei Technology is a leading clinical technology SaaS provider with a clear mission to make clinical research more efficient and accessible for all. We pride ourselves on building solutions that will help you produce the highest-quality clinical data in the fastest, most efficient way, allowing our clients to access and orchestrate accurate end-to-end data in real time. We have a global presence and support, providing sponsors and CROs with innovative clinical research and pharmacovigilance solutions.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account